Xeris Biopharma Holdings (0A8E.L) Stock Price
$3.69 0.1%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
7 -
Technical
6
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Xeris Biopharma Holdings, AI stock picks, stock alerts and much more.
0A8E.L AI Stock Analysis
AI stock analysis for 0A8E.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Xeris Biopharma Holdings (0A8E.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Xeris Biopharma Holdings (0A8E.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Xeris Biopharma Holdings (0A8E.L), currently trading at $3.69, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About 0A8E.L
-
Xeris Biopharma Holdings, Inc.
-
Symbol
0A8E.L
-
Market
LSE
-
Industry
Biotechnology
-
Market Cap
549.4M
Similar Stocks
 |
Codexis 0I0X.L |
$4.27 1% |
3 |
 |
Oxford Nanopore Technologies plc ONT.L |
£134.6 1.7% |
5 |
 |
Sareum Holdings SAR.L |
£19.8 2.9% |
3 |
 |
Viridian Therapeutics 0K1R.L |
$18.64 2.7% |
6 |
 |
Avacta Group Plc AVCT.L |
£46.32 2.5% |
4 |
News
0A8E.L Alternative Data
Web Traffic
Xeris Biopharma Holdings receives an estimated 11208 monthly visitors to xerispharma.com.
-
Web Traffic
11208
-
Change from Previous Month
83.4%
-
3 Month Change
83.9%
News Mentions
Xeris Biopharma Holdings was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
100%
-
1 Month Change
0%
-
3 Month Change
0%
Twitter Followers
Xeris Biopharma Holdings has 967 Twitter Followers on its main Twitter (also known as X) account, which is down by -0.4% over the last month.
-
Twitter Followers
967
-
Daily Change
0.1%
-
1 Month Change
0.4%
-
3 Month Change
1.8%
Facebook Engagement
Xeris Biopharma Holdings has engaged 0 users via their Facebook Page over the last 7 days.
-
Facebook Engagement
0
-
Daily Change
0%
-
1 Month Change
100%
-
3 Month Change
100%
Instagram Followers
Xeris Biopharma Holdings has 806 Instagram Followers on its main Instagram account, up by 1.3% over the last month.
-
Instagram Followers
806
-
Daily Change
0.1%
-
1 Month Change
1.3%
-
3 Month Change
1.3%
LinkedIn Followers
21,348 are following Xeris Biopharma Holdings on LinkedIn, up by 2.2% over the last month.
-
LinkedIn Followers
21348
-
Daily Change
0.1%
-
1 Month Change
2.2%
-
3 Month Change
3.9%
Job Postings
Xeris Biopharma Holdings currenly has an estimated 15 open job postings, up by 50% over the last month.
-
Job Postings
15
-
Daily Change
6.3%
-
1 Month Change
50%
-
3 Month Change
28.6%
LinkedIn Employees
According to LinkedIn, Xeris Biopharma Holdings has 392 employees, down by -0.8% over the last month.
-
LinkedIn Employees
392
-
Daily Change
0%
-
1 Month Change
0.8%
-
3 Month Change
1.3%
Business Outlook
-
Business Outlook
78
-
Change from Previous Month
5.4%
-
3 Month Change
0%
-
YoY Change
0%
0A8E.L Financials
0A8E.L Key Metrics
-
Total Revenue
$54.3M
-
Net Income
-$15.7M
-
Earnings per Share
-$0.11
-
Free cash flow
-$8.4M
-
EBITDA
-$8.2M
-
EBITDA Ratio
-0.150217
-
Total Assets
$321.1M
0A8E.L 2-year Revenue & Income
0A8E.L 2-year Free Cash Flow
0A8E.L Technicals
0A8E.L SMA
0A8E.L RSI
FAQ
What's the current price of Xeris Biopharma Holdings (0A8E.L) Stock?
The price of an Xeris Biopharma Holdings (0A8E.L) share is $3.69.
What's the market cap of Xeris Biopharma Holdings?
The current market cap of Xeris Biopharma Holdings is 549.4M.
Should I buy or sell 0A8E.L?
Multiple alternative data signals suggest that Xeris Biopharma Holdings stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is Xeris Biopharma Holdings a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Xeris Biopharma Holdings stock. The bullish indicators suggest that Xeris Biopharma Holdings' growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy Xeris Biopharma Holdings (0A8E.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Xeris Biopharma Holdings stock, given the bullish outlook.
What are some stocks similar to Xeris Biopharma Holdings (0A8E.L) that investors often compare it to?
Xeris Biopharma Holdings (0A8E.L) is often compared to similar stocks such as Codexis, Oxford Nanopore Technologies plc, Sareum Holdings, Viridian Therapeutics and Avacta Group Plc.
What is the forecast for Xeris Biopharma Holdings' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Xeris Biopharma Holdings' stock price to be around $3.98 in 2026. Starting from the current price of $3.69, this represents a 8% change in price, indicating a bullish outlook for the stock.
How to buy Xeris Biopharma Holdings (0A8E.L) Stock?
Xeris Biopharma Holdings stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Xeris Biopharma Holdings shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.